Page 30«..1020..29303132..4050..»

You are currently browsing the Nano Medicine category

NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

§ February 3rd, 2020 § Filed under Nano Medicine Comments Off on NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the rest here:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Read the Rest...

Recalculating: when research starts one way and ends another – Mirage News

§ February 3rd, 2020 § Filed under Nano Medicine Comments Off on Recalculating: when research starts one way and ends another – Mirage News

Were always told that the journey is just as important as the destination. This is true in many aspects of life, but perhaps nowhere as much as in scientific research. Flexibility, curiosity, and attention to detail can lead to a treasure you werent even expecting to find. TAUs scientists talk about research that began one way and ended another, thanks to a few surprises along the way.

A treasure in a pot

A team of archeologists on an excavation mission found that sometimes, the appearance of a clay pot is no indication of its contents. On one of the excavations in Megiddo, we removed the partitions separating the different sections of the dig and found a whole clay pot full of dirt, says Naama Walzer, a doctoral student in the Department of Archeology and Early Eastern Cultures at Tel Aviv University.

We packed it up and planned to send it to a molecular residue lab to find out what used to be stored inside of this pot, which we dated to around 1100 BCE. The pot was stored in an office, but after a while it became clear that preservation in that area of the excavation wasnt up to standard, so the team decided to empty the pot, in a controlled way, and poured out its contents on the table. We werent expecting to find what ended up being inside: a treasure trove of jewelry, considered one of the greatest troves found in Israel from the Biblical period!

The pot discovered in Megiddo. (Photo courtesy of the Sonia and Marco Nadler Archeology Institute)

Among other things, the trove contained nine large earrings and a seal ring, over a thousand small gold beads, and silver necklaces and jewelry. This is how we found the big treasure of Area H, which is now part of the permanent exhibition at the Israel Museum in Jerusalem, concludes Walzer.

Earrings, rings and gold beads. A huge treasure from the Biblical period. (Photo courtesy of the Sonia and Marco Nadler Archeology Institute)

The longest record in the lowest place

Weve all heard that still water runs deep, but did you know it can run deep enough to be remembered hundreds of thousands of years later? I was looking for places to sample a rock that sank, in a still setting, to the bottom of the Dead Sea, recalls Prof. Shmulik Marco, head of the Porter School of the Environment and Earth Sciences.

The goal was to measure the magnetic properties of the rock in order to reconstruct the changes that have occurred in the Earths magnetic field. This information is essential to understanding one of the most important mysteries in geology. Scientists still have no satisfactory explanation for the mechanism that causes changes in the magnetic field, such as surprising reversals or constant changes in the position of the magnetic poles. While sampling the rocks, I found layers that looked messy. The study took an unexpected turn when I realized the mess was the result of earthquakes, and that became the main focus of the research.

The lowest place: layers of rock at the Dead Sea

Because modern seismographs have only existed for about a century, which is barely a moment in earthquake terms, its impossible to know how a specific area behaves over long periods of time. In Israel, for example, theres documentation from the Biblical period (about 3,000 years ago), which is still considered very little. But now we have a record of the earthquakes that happened around the Dead Sea in the last 220,000 years. Thats considered a unique, world record, because theres no other documentation in the world thats so long and continuous, concludes Professor Marco.

Neat vs messy: A layer of rock in which the natural order was disturbed

A miracle of light

As she was nearing the end of her postdoctoral studies at Yale University, Dr. Ines Zucker of the Iby and Aladar Fleischmann Faculty of Engineering decided to advise an undergraduate student in a promising, short-term study.

But as we all know, the only thing you can count on in life is that everything changes: The purpose of the study was to show a difference in damage to liposomes (microscopic spheres filled by fluorescent fluid and surrounded by a membrane, used in medicine and in scientific studies of biological membranes) by a nanomatter called MnO2, produced in various structures, explains Dr. Zucker.

In the past, weve shown a fluorescent fluid leak (i.e., liposome damage) was dependent on the surface of the nanomatter, and this time we wanted to show it also depended on its structure. But research has its own rules we couldnt find the kind of damage we were looking for. Right as we were about to give up on the study, we took the system to a fluorescence microscope, where we saw that the liposomes and the nanomatter interact in a way weve never seen before in this context: the liposomes envelop the nanomatter, but remain whole, intact spheres without leakage! It was like a miracle of light.

Many times unexpected discoveries surprise us. Dr. Zucker in the lab

A star (re)born

For Dr. Iair Arcavi, of the Department of Astrophysics at the Raymond and Beverly Sackler Faculty of Exact Sciences, a routine evening of surveying space through a robotic telescope led to discovering a brand new phenomenon: the resurrection of a star.

A few years ago, we came across a star that didnt want to die and kept exploding again and again, Dr. Arcavi says. Every night the telescope would find lots of new things, most of them uninteresting. Even with this supernova (which is a star that exploded), we initially thought it was uninteresting, because when the survey first caught it, it was in the dimming stage, and we thought wed missed the interesting part. We noticed for weeks that the supernova was starting to get bright again, which is something that shouldnt happen, so that piqued our interest and made us follow the supernova with additional telescopes.

A supernova exploding far, far away

Usually, when a star explodes, the light intensity goes up and down and eventually disappears after a few months. In our case, the light intensity went up and down, then did it again and again, for a total of five times over two years. What surprised us even more was when we discovered that this star actually exploded in 1954, and after a star explodes, its not supposed to explode again, because the explosion destroys the star. To this day no ones been able to explain it, and we havent seen a similar event since.

The sky is full of surprises: Dr. Arcavi and the Hawaii observatory

Two for the price of one

Have you ever looked for a solution to a problem, only to solve an entirely different problem along the way? Thats exactly what happened to Prof. Noam Shomron of the Sackler School of Medicine.

We wanted to develop a way to identify a specific disease, but along the way we discovered more options, so we made those additional targets of the research, he says. We tracked thousands of pregnant women, to characterize blood molecules that can be early markers of preeclampsia, a condition that can only occur after the 20th week of pregnancy. Not only did we find those molecules, we also managed to characterize other molecules, that could be an indicator of gestational diabetes. (Theres no connection between the two conditions, except that they both occur during pregnancy.)

Whats exciting about this story is that theres still no way of identifying, in the first trimester, using a simple blood test, problems that can occur in the second or third trimester. But our discovery will allow simple blood tests to be developed to identify both conditions, which will then lead to preventative measures at an early stage, and ensure the wellbeing of both mother and baby.

Professor Shomron talking about his accidental discovery at an Atnahta event at TAU

See the original post here:
Recalculating: when research starts one way and ends another - Mirage News

Read the Rest...

Why China Is The Future of Nanoscience – OZY

§ February 3rd, 2020 § Filed under Nano Medicine Comments Off on Why China Is The Future of Nanoscience – OZY

Everything about Chinas drive to become a leading innovator works on a giant scale. Ambitions are enormous, budgets are vast and the focus is widespread. And in many fields, its beginning to close the gap with U.S. and European institutions. But its in the study of materials on the scale of a billionth of a meter nanoscience that China is already fast overtaking its international rivals.

From cloning to cancer research, China is using nanoscience and nanotechnology innovation to drive some of the worlds biggest breakthroughs. In July, an international team of researchers led by Chinese scientists developed a new form of synthetic, biodegradable nanoparticle. Capable of targeting, penetrating and altering cells by delivering the CRISPR/Cas9 gene-editing tool into a cell, the nanoparticle can be used in the treatment of some single-gene disorders, as well as other diseases including some forms of cancer.

In a separate project, scientists at Chinas Nanjing University haveused nanoparticles to target and destroy abnormal proteins known to causebreast cancer. Tests in mice showed the treatment reduced the size of tumors byhalf compared to the control group. At the University of Science and Technologyof China, a team of researchers claims to have given mice infrared night visionby injecting nanoparticles into their eyes.

And at the State Key Laboratory of Robotics in the northeast city of Shenyang, researchers have developed a laser that produces a tiny gas bubble. This bubble can be used as a tiny robot to manipulate and move materials on a nanoscale with microscopic precision. The technology promises new possibilities in the field of artificial tissue creation and cloning.These innovations are backed up by a scale of research thats unmatched. In 2018, Chinese researchers were on their own responsible for 40 percent of all global scientific papers in the field, with the U.S. (15 percent) a distant second.

Nanotechnology supports biomedicine and quantum technology development and makes its way into everyday life through advancements in consumer electronics and artificial intelligence, all areas where China seeks global dominance. Being at the forefront of cutting-edge nano research greatly improves Chinas prospects for success, especially in biomedicine, where it has long trailed rivals.

Drug delivery, nanomedicine and tissue engineering are rapidly growing fields that rely on our ability to engineernanoparticles and biomaterialstargeted at specific cells, such as cancer cells,to enhance the therapeutic efficacy, says Dr. Omid Kavehei, deputy director of the University of Sydney Nano Institute.

Chinas gains could help it win critical patents in advanced research in fields like cancer, where the U.S. has historically led.

Strong state support in nanoscience as in tech fields such as artificial intelligence and robotics is also a key advantage for China, Bai Chunli, president of the Chinese Academy of Sciences (CAS), conceded publicly in August. The importance the government places on competitiveness in the field is underlined by its inclusion as a strategic industry in Chinas 13th Five-Year Plan, ensuring state funding and legislative and regulatory support. Nanotech research is also a key component of the ambitious Made in China 2025 initiative aimed at turning China into a high-tech manufacturing powerhouse.

Thats allowing China to find success in myriad areas of nanotechnology. A new nanomaterial invented by CAS scientists promises to eliminate millions of metric tons of liquid pollution and emissions from organic chemicals used in printing plates and ink. It is one of the headline acts for CAS as it drives to apply nanotechnology innovation to the development of consumer tech. So far, the project has landed $780 million in investment.

China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology.

Shengfu Yang, University of Leicester

In an October 2019 paper published by science journalNano Energy, Dalian Institute of Chemical Physics announced the creation of a tiny lithium battery that is resilient to low temperatures, capable of operating at 80 percent efficiency at temperatures of -40 degrees Celsius. While the battery presents huge potential for industries from electric cars to mobile devices, the ability of the battery to operate at extreme temperatures is particularly important to the future of space technology.

Industry experts point to the return of foreign-trained Chinese researchers to the Middle Kingdom, lured by the promise of readily available funding, as an important factor of Chinas progress. The next step is for China to become self-sufficient in developing talent. Currently China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology, says Shengfu Yang, nanochemistry professor at the University of Leicester. The nanoparticle that delivers the gene-editing tool into cells was developed in partnership with scientists at Tufts University in the United States, for instance.

Enhancing innovation in the private sector will also help China kick on, says Zheng Xiao Guo, professor of chemistry and mechanical engineering at the University of Hong Kong. State-funded institutions have played a far bigger role in nanotechnology innovations, and private institutions or enterprises in this area are not as strong, he says.

But the number of private companies driving nanotech product innovation is rapidly growing, Zheng concedes. Nanopolis, the worlds largest nanotech industrial zone, located in the eastern city of Suzhou, houses several private multinationals and new Chinese startups across nanotech fields. China now also leads the globe in newly established nanotech companies. In 2018, Tencent founder Ma Huateng joined a number of high-profile businesspeople in financing the establishment ofChinas first private research institute,Westlake University, with nanotech a main focus for research.

Private-sector involvement opens new and unique pools of funding and talent, and the focus is on applicable research even in a country like China, where state-sponsored institutions still dominate, say experts.

That combination of a growing talent pool and a state-sponsored desire to become a global leader, with an expanding private-sector ecosystem, will be hard for other countries to match. Chinas big leap in small science is just starting.

Read this article:
Why China Is The Future of Nanoscience - OZY

Read the Rest...

Stephen Moore: President Trump, THIS is our economy’s unsung hero – Fox Business

§ February 3rd, 2020 § Filed under Nano Medicine Comments Off on Stephen Moore: President Trump, THIS is our economy’s unsung hero – Fox Business

Federal Reserve Chairman Jerome Powell speaks about U.S. economic growth during a press conference and says the Fed will leave rates unchanged.

At the World Economic Forum in Davos, Switzerland, last week, President Donald Trump again talked positively about negative interest rates. That's not a very good idea considering negative interest rates are a warning signal of deflation, which can be as bad for an economy as runaway inflation.

But Trump was right to herald this era of low nominal interest rates and inflation. If you want to understand how the Dow Jones Industrial Average has risen from a low of 800 to a high of 29,000 in four decades, look at the Federal Reserve's graph of the 10-year treasury rate showing the sharp and relentless decline in interest rates between 1980 and 2020. Think about how the world has changed. In 1981, 10-year Treasury bills paid an interest rate of 16%. Now they are at 2%.

DOW TUMBLES 600 POINTS AS CORONAVIRUS FEARS ROCK STOCKS

It may be the biggest unsung story of economic success -- a gift that just keeps on giving.

The biggest winner of all from low rates is, of course, Uncle Sam. Every 1-percentage-point reduction in interest rates reduces federal borrowing costs by at least $1 trillion over a decade.

I remember in the early 1980s, my local bank was trying to lure depositors by offering lifetime certificates of deposit paying 10% to 12% interest rates. Many of the banks that made such foolish offerings failed in the years to come. What happened? Federal Reserve Chairman Paul Volcker teamed together with Ronald Reagan in a political partnership that slew inflation, bringing it down from 12% to 4% in about 18 months.

The high nominal interest rates back then were simply the price we all paid for runaway inflation, which rose to 12% in 1980. The consensus among economists and leading financiers was that double-digit inflation was with us for decades to come -- as Paul Samuelson warned about in his weekly Newsweek column.

Whoops. What was not foreseen was that Reagan and Volcker would start a new economic regime to kill inflation that prevails to this day. We now live in an era with interest rates lower than at any time in decades, and the forecast is for borrowing costs, which are driven primarily by inflation and inflationary expectations, to remain microscopic for years and decades to come.

CORONAVIRUS UNDERMINES HEALTH OF U.S. ECONOMY: GOLDMAN SACHS

Why do these low rates matter to the economy? Let's start by imagining the added cost to buying or selling a home today if we still had mortgage rates as high as they were back then. Homeowners would be paying thousands of dollars of extra mortgage payments a year, and real estate values would crash, as would homebuilding.

Second, low-interest rates raise stock values and wealth. Inflation and high-interest rates are the thieves of the stock market. The towering inflation of the late 1960s through 1980 corresponded with a near-60% collapse in the after-inflation return on stocks. It was one of the greatest liquidations of wealth in U.S. history -- a bloodbath. Disinflation and falling interest rates combined with a stable dollar have helped resurrect growth while U.S. assets (owned by the public) have reached $100 trillion in value.

Third, low-interest rates reduce the cost of borrowing costs for businesses and allow small firms that might not have access to equity markets to expand investment through loans. By the way, real (inflation-adjusted) interest rates rise when there is a higher demand for credit, which happened in the 1980s even as nominal rates plummeted.

The biggest winner of all from low rates is, of course, Uncle Sam. Every 1-percentage-point reduction in interest rates reduces federal borrowing costs by at least $1 trillion over a decade. A sudden spike in rates by, say, 200 basis points, which would still be below the historical average in the post-World War II era, means $2 trillion to $3 trillion of higher interest expenditures on top of $20 trillion of publicly traded debt.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

A final point: I keep hearing senior citizens and financial advisers complain that low-interest rates hurt retirees on fixed incomes. That's nonsense. Seniors tend to hold more stocks than young people, so the surge in stock values has disproportionately benefited older people in the United States. Seniors who complain about today's low returns on bonds should be taking a look at how their stock portfolios are performing. In just three years under Trump, index funds have seen better than a 50% return. Some $60 trillion of wealth is held by seniors today and will soon be passed on to the younger generations thanks to this 40-year surge in the stock market.

In the 1970s, seniors living on fixed incomes were supposed victims of high inflation and interest rates because it cost them more to buy food, medicine and energy. Higher interest rates would correspond with a higher cost of living, so seniors should be careful of what they wish for.

So should Trump. His administration is benefiting mightily from low rates and tame inflation -- to which his supply-side policies, including tax cuts, have contributed. But negative rates would mean falling prices, and the last time that happened, the nation found itself heading into the Great Depression.

Stephen Moore is a senior fellow at the Heritage Foundation and an economic consultant with FreedomWorks. He is the co-author of "Trumponomics: Inside the America First Plan to Revive the American Economy."

CLICK HERE TO READ MORE ON FOX BUSINESS

Original post:
Stephen Moore: President Trump, THIS is our economy's unsung hero - Fox Business

Read the Rest...

High-resolution Melting Analysis Market Size, Application, Region and Growth Forecast 2017-2025 – Science of Change

§ February 3rd, 2020 § Filed under Nano Medicine Comments Off on High-resolution Melting Analysis Market Size, Application, Region and Growth Forecast 2017-2025 – Science of Change

High-resolution Melting Analysis Market: Snapshot

The global market for high-resolution melting analysis is gaining momentum on account of the advancements in molecular biology. High-resolution melting analysis involves the microscopic study of double-stranded DNA samples to successively detect polymorphisms, epigenetics, and mutations. The study involves the amplification of the region where the mutational analysis needs to be carried out and generation of multiple copies of that region in the sample tube. The applications of high-resolution melting analysis in molecular biology are expansive, which is expected to play to the advantage of the market. TMR Research throws light on several market forces that are expected to contribute to the growth of the market over the coming. Moreover, a multifaceted approach to understand the knit and grit of the market was followed during research and analysis.

Request Sample of High-resolution Melting Analysis Market Report for more Industry Insights @CLICK HERE NOW

One of the most important applications of point high-resolution melting (HRM) analysis is the detection of point mutation. The conventional method of SNP typing is expensive and time-consuming which shifts the focus on HRM analysis. Testing of zygotes has also emerged as an important application of HRM analysis, which is propelling demand within the global market. Apart from the above-mentioned applications, intercalating dyes used for the transition of double-standard DNAs to single-stranded ones are another key area that is projected to contribute to the growth of the market.

Genetic testing centers have been specifically very successful in North America which has given an impetus to the market. On the other hand, prominence of academic Institutes and research centers in Europe has also contributed to the growth of the regional market.

Global High-resolution Melting Analysis Market: Overview

High resolution melting analysis is a powerful and strong methodology in molecular biology for the purpose of detecting epigenetic differences, polymorphisms, and mutations in double-stranded DNA samples. It was first discovered and developed by the Idaho Technology and University of Utah. High resolution melting analysis has several advantages over genotyping technologies such as cost effectiveness, it is powerful and fast as compared to genotyping technologies, and it is comparatively simple. Based on products and services, the global high-resolution melting analysis market can be segmented into software and services, consumables and reagents, and instruments. In terms of application, it can be segmented into epigenetics, pathogen identification, species identification, mutation scanning, and SNP genotyping.

The global market for high-resolution melting analysis is likely to have a fruitful future owing to ongoing research and developments in this field sponsored by several leading companies operating in this particular field. For instance, FDA in the U.S. approves many treatments which are made for addressing a specific genomic profile or genetic makeup of the tumor of the patient.

Global High-resolution Melting Analysis Market: Drivers and Restraints

The prime factors that are boosting the growth of the market comprise the growing prevalence of cardiovascular diseases, COPD, chronic diseases such as cancer, and other different infectious diseases. The prime benefits associated with high-resolution melting analysis are optimization of therapies, patient compliance, drug safety, cost savings on several treatments, and disease diagnosis. In return, these are also expected to propel the demand for DNA testing services. Moreover, rising awareness pertaining to the applications of high resolution melting analysis technologies for HLA typing, mutation discovery, and DNA mapping are additional aspects that are anticipated to propel the growth of the high-resolution melting analysis market during the forecast period. High resolution melting analysis is a technology employed for assessing melting curve plots of amplified gene. This particular technology is basically used for gene mutation scanning, microbial species identification, methylation profiling, and other different diagnostics based on PCR. Thus, mutation scanning and other applications are likely to gain prominence over time owing to rising prevalence of advancements in technology of molecular biology, genetic disorders, and growing awareness pertaining to SNP typing.

Global High-resolution Melting Analysis Market: Market Potential

Growing government budget provision for research and development in the field of pharmaceuticals, biotechnology, and applied life sciences is a crucial factor heightening the demand for numerous diagnostic techniques and tools. For instance, in 2015, the Obama led administration announced the introduction of the Precision Medicine Initiative with a huge investment of US$216 mn in the Presidents budget of 2016. This initiative is further expected to have positive impact on the growth of the high resolution melting analysis market.

Global High-resolution Melting Analysis Market: Regional Overview

Region-wise, the market can be segmented into North America, Asia Pacific, Europe, and the Rest of the World. North America is expected to perform extremely owing to factors such as robust adoption of advanced technology in healthcare, numerous genetic testing centers, strong biotech and pharmaceutical industry, prevalence many academic universities, and high prevalence of diseases. Asia Pacific has also been identified as one of the potential regions where the market can grow steadily owing to dynamics such as rising prevalence of chronic diseases such as HIV, COPD, and cancer, growing cases of genetic disorders, and rising private and public expenditure on genetic testing and molecular diagnostic.

Get TOC of High-resolution Melting Analysis Market Report for more Industry Insights @CLICK HERE NOW

Global High-resolution Melting Analysis Market: Competitive Landscape

The top drawer companies operating in the market areThermo Fisher Scientific, Kapa Biosystems, Idaho Technology Corporation, and Roche Molecular Systems.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

More here:
High-resolution Melting Analysis Market Size, Application, Region and Growth Forecast 2017-2025 - Science of Change

Read the Rest...

This one thing may be raising your risk of getting Alzheimers – MarketWatch

§ February 1st, 2020 § Filed under Nano Medicine Comments Off on This one thing may be raising your risk of getting Alzheimers – MarketWatch

If you want to avoid getting dementia or Parkinsons disease, get out of town. Literally.

A new scientific study in Canada has added to the growing body of data that people who live in polluted or urban settings, especially if they live near major roads and far away from any parks, may be at a higher risk of developing Alzheimers, other forms of dementia, Parkinsons disease, or multiple sclerosis.

Researchers found increasing patterns of associations between living close to major roads and the so-called hazard and odds of developing non-Alzheimers dementia, Parkinsons disease, Alzheimers disease and multiple sclerosis, write researchers Weiran Yuchi, Hind Sbihi, Hugh Davies, Lilliam Tamburic and Michael Brauer in the peer-reviewed biomedical journal Environmental Health.

Living within 50 meters of a major road, or 150 meters of a highway, seem to be major risk factors, Brauer, a professor of medicine at the University of British Columbia, confirmed to MarketWatch. The study found that people whose homes met those conditions 19% more likely to develop Alzheimers, 14% more likely to develop other forms of dementia, 7% more likely to develop Parkinsons, and 25% more likely to get multiple sclerosis, he said.

The study was based on health and living data of 678,000 people in Vancouver, British Columbia from 1994 to 2003. Because British Columbia has near universal health care, researchers were able to get detailed health data for individuals, and compare it with data about exactly where they lived. Location information included estimates for traffic pollution and for the amount of green spaces in the neighborhood.

The latest study isnt the first in recent years to find a connection between pollution, urban living, and neurological damage.

Most air pollutants and traffic noise were associated with overall MCI [Mild Cognitive Impairment], found researchers in Germany after a study of nearly 5,000 older people. Ambient traffic-related air pollution was associated with decreased cognitive function in older men, found a study of nearly 700 people in the U.S. An 15-year study conducted in Sweden, based on more than 1,800 people, concluded that air pollution from traffic might be an important risk factor for vascular dementia and Alzheimers disease. Researchers in the U.S. found a decade ago that stroke incidence, and Alzheimers and Parkinsons disease pathology are linked to air pollution.

The ways that pollution could increase someones chances of developing dementia, Parkinsons and other diseases of the brain and nervous system are not yet fully understood. But scientists say pollution including microscopic particles, lead, carbon monoxide, sulfur dioxide, nitrogen dioxide and oxone is known to effect the lungs and cardiovascular system as well as the central nervous system directly.

In addition to the human tragedy, experts note that Alzheimers and other forms of dementia also pose a high and rising risk to society overall as life expectancy rises and the population ages. People are more likely to develop dementia as they age. Those with dementia can live for many years with the disease before dying, needing round the clock skilled care.

Caring for relatives who have dementia can put an enormous burden on other members of the family, including a spouse and children, causing depression and other health issues for them in turn. The financial implications can be enormous. Many of those caring for a relative with dementia directly will be unable to hold full-time jobs.

Meanwhile nursing homes typically cost around $100,000 a year, far beyond the reach of most families. Medicare does not pay for long-term nursing home care. Once families have spent most of their money, the costs will then fall on U.S. taxpayers through Medicaid.

A recent study argued that dementia is already costing the U.S. about $300 billion a year, and the world overall more than $800 billion, or more than 1% of total annual output. The number of Americans with Alzheimers alone is forecast to double over the next 30 years from 5.8 million to more than 13 million.

See the rest here:
This one thing may be raising your risk of getting Alzheimers - MarketWatch

Read the Rest...

Digital Movie Cameras Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2026 – Technology Magazine

§ January 31st, 2020 § Filed under Nano Medicine Comments Off on Digital Movie Cameras Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2026 – Technology Magazine

The New Research Report on Global Digital Movie Cameras Market till 2026 added by Market Study Report LLC studies the current and upcoming Market Size, Share, Demand, Growth Trend and Forecast.

This report on the Digital Movie Cameras market specifies details about the industry in terms of a thorough evaluation and an in-depth assessment of this business. An overview of the industry with regards to the market size in terms of the renumeration and volume aspects, along with the current scenario is inculcated in the report.

Request a sample Report of Digital Movie Cameras Market at:https://www.marketstudyreport.com/request-a-sample/2420230?utm_source=technologymagazine.org&utm_medium=sp

The report also provides a brief related to the geographical spectrum of this vertical along with the firms that have received a significant stance across the marketplace.

An outline of the Digital Movie Cameras market scope:

Synopsis of the competitive landscape:

.

Ask for Discount on Digital Movie Cameras Market Report at:https://www.marketstudyreport.com/check-for-discount/2420230?utm_source=technologymagazine.org&utm_medium=sp

Analysis of the regional expanse:

Brief of the market segmentation:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-digital-movie-cameras-market-research-report-2020

Some of the Major Highlights of TOC covers:

Digital Movie Cameras Regional Market Analysis

Digital Movie Cameras Segment Market Analysis (by Type)

Digital Movie Cameras Segment Market Analysis (by Application)

Digital Movie Cameras Major Manufacturers Analysis

Related Reports:

1. Global Ultra HD High Speed HDMI Cable Market Research Report 2020This report categorizes the Ultra HD High Speed HDMI Cable market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-ultra-hd-high-speed-hdmi-cable-market-research-report-2020

2. Global PCI Express Interface Cards Market Research Report 2020PCI Express Interface Cards Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of PCI Express Interface Cards by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-pci-express-interface-cards-market-research-report-2020

Related Reports: https://www.marketwatch.com/press-release/650-growth-for-radiotherapy-market-size-is-expected-to-exhibit-us-123-billion-by-2025-2020-01-30

Related Reports: https://www.marketwatch.com/press-release/6-growth-for-nanomedicines-market-size-is-expected-to-exhibit-us-1955-million-by-2025-2020-01-30

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Digital Movie Cameras Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2026 - Technology Magazine

Read the Rest...

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus – Yahoo Finance

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus – Yahoo Finance

With the outbreak of the Wuhan coronavirus in China and the increasing death toll, there is little doubt that global financial markets are going to be impacted negatively. As Trump considers banning all flights to China, airline and travel companies like United Airlines (NASDAQ:UAL), Expedia (NASDAQ:EXPE), American Airlines (NASDAQ:AAL) and many more have seen their stock prices crash. There is a strong negative sentiment on the Chinese economy as a whole as the virus has shaken up many of the erstwhile strong sectors.

Overview of the virus

For those readers who are not aware, the Wuhan coronavirus first emerged in the central Chinese city of the same name through the meat and seafood markets and has spread across the country with over a thousand cases and more than a hundred deaths confirmed. It belongs to the same family of viruses as SARS (severe acute respiratory syndrome) and the MERS (Middle East respiratory syndrome). This group of crown-shaped viruses can become deadly if it causes the patient to develop lower respiratory tract illnesses such as pneumonia or bronchitis. It is highly contagious in nature, spreading through the slightest form of saliva contact, whether it is coughing or kissing. The story of the Wuhan coronavirus sounds like history repeating itself after SARS shook up global markets in 2002-03.

It is worth recalling that pharma and biotech companies catering to the respiratory system and providing anti-viral medications were the ones that appreciated the most during the time of SARS, and the current situation does not appear very different. With a strong negative sentiment prevailing in most other sectors, pharma and biotech are perhaps the only sectors that could get a boost from a new bullish sentiment resulting from this virus. Based on the nature of the virus and the expected treatments, the following four stocks could benefit hugely given their presence in the field of anti-viral respiratory medication.

GlaxoSmithKline plc

Since the Wuhan coronavirus belongs to the same family as the SARS, it is important to recall those companies which benefitted the most from the SARS outbreak. While SARS may not have a defined cure even today, the most commonly prescribed form of treatment is the same as that for pneumonia. GlaxoSmithKline plc (NYSE:GSK) is one of the leaders in the space of anti-viral treatments for respiratory disorders like pneumonia.

The above chart shows how the company's stock grew as much as 35% during the SARS phase, which is quite significant for its size. It is worth highlighting that GlaxoSmithKline is a global player with its biggest markets being the U.S. and the UK. Respiratory oral health is one of its strongest segments, and it has a monopolistic position in many anti-viral medications. For example, its Shingrix vaccine for shingles is the only preventive vaccine for the disease across the globe. It has also performed strong research on HIV. The stock has appreciated by over 20% in the past twelve months and also provided a dividend yield of 4.32%, making it an excellent bet for investors.

Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is more of a play on the diagnostics aspect rather than the treatment aspect of the Wuhan virus. The company is one of the largest global biotech giants, and one of its most important offerings relevant to the Wuhan virus situation is its diagnostic capabilities. Abbott is known to provide rapid diagnostics systems for infectious diseases along with remote patient monitoring, informatics and automation solutions that are all very relevant to diagnose the Wuhan virus victims. It also has molecular point-of-care testing for HIV, influenza A and B and RSV.

Story continues

Abbott's relevance was so strong in the SARS era that it appreciated by over 30% in those times and is already up by around 22% in the past 12 months. Given the current situation, the upward momentum of the stock might continue for a while.

Gilead Sciences, Inc.

Biotech giant Gilead Sciences, Inc. (NASDAQ:GILD) was easily one of the biggest beneficiaries in the SARS outbreak, as it saw its stock appreciate more than 200% throughout the outbreak.

The reason for this appreciation is that Gilead gets most of its revenues from the anti-viral segment. The company's stock price has been stable throughout economic downturns and it is not without reason that the company has a 4.5-star business predictability rating on Gurufocus. Not only is it debt-free, it is known to distribute a good amount of dividend (current yield of 3.93%) to shareholders over and above capital appreciation. Not only has it done remarkable research on HIV, Gilead also has some very well known anti-viral brands in the market such as Atripla, Cayston, Sovaldi, Odefsey, Truvada, Biktarvy and so on. It is certainly going to be moving fast in the race to provide strong anti-viral treatments for the Wuhan coronavirus.

NanoViricides, Inc.

NanoViricides, Inc. (NNVC) is the only small, development-stage company on this list, but it is here for a reason. Since the news of the Wuhan virus outbreak, NanoViricides has seen its stock shoot up by as much as 349%.

The company, led by biotech veteran Dr. Anil Diwan, specializes in anti-viral research and had actively worked on MERS in the past. Its current research is also focused on treating viruses through its proprietary nanomedicine technology, where it uses anti-viral nanomachines known as "nanoviricides." The company has a decent pipeline of anti-viral drug candidates catering to diseases such as shingles, herpes, seasonal and potentially-epidemic influenzas, bird flu, HIV, cold sores, viral eye diseases and dengue viruses.

In fact, its most rapidly advancing drug candidate is a topical cream for the treatment of shingles, which is now advancing to the stage of IND application before progressing to human trials. While the company may not have significant revenues today, it hopes to start monetizing the progress of this cream through licensing agreements after the initial phases of the human trials. It has been one of the biggest beneficiaries of the Wuhan virus outbreak so far in terms of stock appreciation, and the upward momentum is expected to remain strong with the IND application results arriving soon.

Conclusion

The Wuhan coronavirus may have a huge negative impact on global markets over a span of time, but the pharma and biotech space is one where it presents a good opportunity. As its fears grip the world, companies like the ones mentioned above are working hard to capitalize on this opportunity and maximize their revenues. In such a situation, it is often beneficial for investors to be opportunistic and make the most returns through investing in these companies.

Disclosure: No positions.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.

Excerpt from:
These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus - Yahoo Finance

Read the Rest...

Nanomedicine Market: Industry Analysis and forecast 2026 – Expedition 99

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market: Industry Analysis and forecast 2026 – Expedition 99

Nanomedicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39223

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

by Modality:

Diagnostics Treatmentsby Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological Diseases

by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives Oncology

by Region:

Asia Pacific North America Europe Latin America Middle East Africa

Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

More:
Nanomedicine Market: Industry Analysis and forecast 2026 - Expedition 99

Read the Rest...

Global Nanorobotics Market : Industry Analysis and Forecast (2018-2026) – Expedition 99

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Global Nanorobotics Market : Industry Analysis and Forecast (2018-2026) – Expedition 99

Global Nanorobotics Marketwas valued at US$ 3.7 Bn in 2017 and is expected to reach US$ 9.2Bn by 2026, at a CAGR of 12.06%during a forecast period.Global Nanorobotics MarketDevelopments in nanotechnology coupled with demand for minimally aggressive procedures are expected to drive market growth over the forecast period. Nanobots possess likely in the medical sector for destroying cancerous cells at the genetic level. Increasing support for nanomedicine by many nations and the increasing geriatric population are factors which can augur market demand.

Utilization of nanobots in the ranostics can be beneficial for the market in the near future. A rise in miniaturization and demand for automation across various sectors are anticipated to fuel market growth. Training of new personnel to use nanobots can restrain market growth in the upcoming years.Nanomedicine application segment to grow at the highest CAGR during the forecast period. Nanorobotics is widely used in nanomedicine owning to its healthcare features. The large share of this application aspects to the large level of commercialization in the healthcare sector for drug delivery, in vivo imaging, biomaterial, in vitro diagnostic, active implants, and drug therapy.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/30888

North America region accounted for the largest share of 12.2%, in terms of value, of the nanorobotics market globally. Presence of many nanotechnology companies, well-developed healthcare infrastructure, and government initiatives to create patient awareness are factors driving the market. The U.S is anticipated to contribute to market revenue owing to the increase in cardiovascular diseases and the rising elderly populace.

Europe follows North America as the second biggest nanorobotics market. Presence of chronic diseases and the burgeoning population are factors expected to indicate the Europe nanobots market. Establishment of organizations to develop standards pertaining to nanotechnology can expand market growth. In 2018, DNA-Robotics, an organization including 12 European companies, has outlined steps to expedite production of nanobots on a large scale. These standards can help scale the market exponentially in the upcoming years.

A recent development in nanorobotics market: In March 2018, Thermo Fisher Scientific acquired Gatan, an exclusively owned subsidiary of Roper Technologies. Gatan is an electron microscopy solutions provider in the U.S, which accompaniments the Thermo Fisher Scientifics electron microscopy solutions business.In March 2017, Oxford Instruments (U.K) Asylum Research introduced its new SurfRider HQ-Series of high quality, budget-priced AFM probes, which are also existing in a model suitable for nanomechanical image mode.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Nanorobotics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Nanorobotics Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/30888

Scope of the Global Nanorobotics Market

Global Nanorobotics Market, By Type

Nanomanipulatoro Electron Microscope (EM) Scanning Electron Microscope (SEM) Transmission Electron Microscope (TEM)o Scanning Probe Microscope (SPM) Atomic Force Microscopes (AFM) Scanning Tunneling Microscope (STM) Bio-Nanorobotics Magnetically Guided Bacteria-BasedGlobal Nanorobotics Market, By Application

Nanomedicine Biomedical Mechanical OthersGlobal Nanorobotics Market, By Region

North America Europe Asia Pacific Middle East and Africa South AmericaKey players operating in Global Nanorobotics Market:

Bruker JEOL Thermo Fisher Scientific Ginkgo Bioworks Oxford Instruments EV Group Imina Technologies Toronto Nano Instrumentation KlockeNanotechnik KleindiekNanotechnik Xidex Synthace Park Systems Smaract Nanonics ImagingKey Innovators:

Novascan Technologies Angstrom Advanced Hummingbird Scientific NT-MDT Spectrum Instruments Witec

Browse Full Report with Facts and Figures of Nanorobotics Market Report at:https://www.maximizemarketresearch.com/market-report/global-nanorobotics-market/30888/

MAJOR TOC OF THE REPORT

Chapter One: Nanorobotics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanorobotics Market Competition, by Players

Chapter Four: Global Nanorobotics Market Size by Regions

Chapter Five: North America Nanorobotics Revenue by Countries

Chapter Six: Europe Nanorobotics Revenue by Countries

Chapter Seven: Asia-Pacific Nanorobotics Revenue by Countries

Chapter Eight: South America Nanorobotics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanorobotics by Countries

Chapter Ten: Global Nanorobotics Market Segment by Type

Chapter Eleven: Global Nanorobotics Market Segment by Application

Chapter Twelve: Global Nanorobotics Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

The rest is here:
Global Nanorobotics Market : Industry Analysis and Forecast (2018-2026) - Expedition 99

Read the Rest...

Trying to Figure Out the Scoop on Poop – Tufts Now

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Trying to Figure Out the Scoop on Poop – Tufts Now

For most humans and animals, diarrhea is an uncomfortable but minor problem. However, in horses, diarrhea can more easily turn deadlykilling some 25 to 30 percent of affected animals. Thats because horses often lose a large volume of fluid and are extremely sensitive to toxins that come from bacteria in their gut, said Caroline McKinney, V16, MPH16, an internal medicine resident at Tufts Equine Center.

Now an experimental treatment borrowed from human medicine has appeared so promising in helping horses with diarrhea that it has become standard practice at Cummings School.

In the therapycalled fecal microbiota transplantation (FMT)veterinarians take manure from a healthy donor horse and put it in the gut of the horse with diarrhea. Although exactly how FMT works has yet to be determined in veterinary or human medicine, the hypothesis is that it repopulates a patients depleted gut bacteria to restore its natural species richnessnormalizing the gastrointestinal microbiome.

This internal ecosystem is made up of hundreds of species of bacteria, fungi, and protozoa that work either for or against our health. Indeed, the variety of flora in the gut is one of the things that makes treating diarrhea so tricky, especially when its related to bacterial overgrowth: antibiotics, which are typically used in the fight against bacterial infections, kill off many bacteria, beneficial and harmful bugs alike. That can exacerbate and prolong the course of diarrheal disease, and it may even contribute to antibiotic resistance down the road, McKinney explained.

Scientists reason that adding healthier, more diverse microorganisms to the gut helps rein in any diarrhea-causing bacteria, and research supports this view. In a systematic review of its clinical use in people, fecal transplants cured upward of 80 percent of antibiotic-resistant infections caused by Clostridium difficile, a potentially deadly diarrheal superbug.

Versions of fecal transplants have been practiced in human medicineand even for animalsfor a long, long time, McKinney said.

Eastern medicine has been doing a form of fecal transplant for centuries in people, she said. And young foals instinctively eat mares manure to establish their gut flora. Veterinarians also routinely perform another kind of gut-flora transplant in ruminant species such as cows, alpacas, and sheep. Cummings School keeps a donor cow, named Annabel, to treat sick animals in this way.

For the treatment in horses, about two pounds of manure is collected from a healthy donor horseone thats been carefully tested for parasites or any concerning bacteria or viruses. It is then mixed with a few liters of water to create a poop soup, as the hospital staff laughingly call it. The liquid teeming with microscopic life is then delivered into the sick horses gut via a stomach tube that goes through the nose.

The clinical success of FMT at Tufts Equine Center was first evaluated in 2017, using a small retrospective study conducted by Professor Melissa Mazan, V93. Based on favorable results, McKinney said she became interested in FMT during the first year of her residency at Tufts Cummings School, a leading academic training and research center in New England.

Veterinarian Sophie Sage, the senior resident there at that time, was also a proponent of the treatment.

Together, we became known in the hospital as the poop queens, McKinney said.

Although the clinical impression at Tufts Equine Center is that fecal transplant is effective in treating horses with diarrhea, its clinician-scientists wanted to look closer into the effects of fecal transplant on the gut of treated horses. So Cummings School researchers decided to see if it was possible to document the effects and mechanisms of this therapy.

The research was led by Associate Professor Daniela Bedenice, a specialist in large-animal medicine and emergency and critical care, and Professor Giovanni Widmer, a molecular biologist who was the first to sequence the genome of Cryptosporidium, a waterborne bacterium that causes diarrhea in humans and animals.

This a truly collaborative project in that we couldnt conduct such a study without each others expertise, Bedenice said. As clinician-scientists at Tufts Equine Center, we know which questions wed like to answer to advance patient care, because we are faced with life-threatening illness in horses every day. While we rely on the entire hospital team for our animal work, Giovanni was our go-to specialist when it came to microbiome analyses.

In a small pilot study, horses with diarrhea were treated with three consecutive daily fecal transplants. Widmer and Ph.D. student Bruno Oliveira conducted genetic analyses on fecal samples taken from the horses before and each day after being treated with FMT. They analyzed samples from the healthy donor horses as well.

By analyzing the bacterial DNA in the stool of horses with colitis, Widmer and Oliveira showed that the microbiota in horses with colitis is very diverse between individuals and differs from the microbiome of healthy horses.

Although successful FMT treatment does not necessarily result in the donor and recipient horses microbiomes becoming exactly the same, there appears to be a relationship between the type of bacteria repopulating the gut in treated horses and the fecal bacteria that the donor has given them, Bedenice said. Analysis of the bacterial DNA from the stool of the patients whose diarrhea resolved after FMT showed that the microbiota changed to more closely resemble the donor's bacterial community.

The study results have since been presented at the Havemeyer Workshop on Acute Colitis in the Adult Horse and submitted to a scientific journal for peer-review. The Cummings School researchers say theyre particularly interested in investigating the potential for using the good species of bacteria associated with resolution of diarrhea as a probiotic.

In a follow-up studyfunded as a Resident Research Award by the American College of Veterinary Internal Medicinethe team now is looking at the effects of fecal transplant in a larger population of horses. They seek to establish whether this treatment helps normalize both clinical signs and the type and diversity of gut bacteria found in horses with diarrhea. The researchers also plan to compare serial samples taken from horses being treated with FMT at Tufts and samples from horses seen for colitis at the Oregon State University, where FMT is not in routine use.

Treating a horse with diarrhea can be expensive, McKinney said. Therapy often requires large volumes of IV fluids, and horses must be isolated from other patients at least until communicable causes have been ruled out. Sometimes horses must remain in an isolation unit until their condition completely resolves, given the risk of contaminating equipment used for other animals.

When horses stop having diarrhea after fecal transplant, its such a thrill to be able to call their owners and say they don't have to be in full isolation anymore, which is an additional weight off their shoulders and also less costly, McKinney said.

Thats why Bedenice said that even though the concept of FMT treatment and research can initially be a bit hard to digest, the research is so rewarding.

Genevieve Rajewski can be reached at genevieve.rajewski@tufts.edu.

Read more from the original source:
Trying to Figure Out the Scoop on Poop - Tufts Now

Read the Rest...

Bioelectric Medicine Market Projected to Witness Vigorous Expansion by 2017-2027 – Dagoretti News

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Bioelectric Medicine Market Projected to Witness Vigorous Expansion by 2017-2027 – Dagoretti News

Business Intelligence Report on the Hypo Anti Allergic Baby Food Market

FMI, in a recently published market study, offers valuable insights related to the overall dynamics of the Hypo Anti Allergic Baby Food Market in the current scenario. Further, the report assesses the future prospects of the Hypo Anti Allergic Baby Food by analyzing the various market elements including the current trends, opportunities, restraints, and market drivers.

As per the report, the Hypo Anti Allergic Baby Food Market is set to grow at a CAGR of ~XX% over the forecast period 2017-2027 and exceed a value of ~US$ XX by the end of 2029. The report suggests that significant progress in technology, growing investments towards R&D projects, and increasing awareness related to curbing industrial waste are some of the primary factors that are expected to drive the growth of the Hypo Anti Allergic Baby Food Market during the assessment period 2017-2027.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.futuremarketinsights.co/reports/sample/REP-GB-2715

The presented report offers a microscopic view of the market scenario in different regions. The political and economic environment are thoroughly assessed to provide clarity on the growth prospects of the Hypo Anti Allergic Baby Food market in each regional market.

Key Information that can be drawn from the Hypo Anti Allergic Baby Food Market Report:

This chapter of the report tracks the business prospects of prominent market players operating in the Hypo Anti Allergic Baby Food Market. The revenue growth, market share, product portfolio, pricing, sales, and marketing strategies of each company is discussed in the report.

Important queries related to the Hypo Anti Allergic Baby Food Market addressed in the report:

Get Access To TOC Covering 200+ Topics athttps://www.futuremarketinsights.co/toc/REP-GB-2715

key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Customized Report As Per Your Requirements athttps://www.futuremarketinsights.co/customization-available/REP-GB-2715

Why Companies Trust FMI?

About Us

FMI is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us

616 Corporate Way, Suite 2-9018,Valley Cottage, NY 10989,United StatesT: +1-347-918-3531F: +1-845-579-5705T (UK): + 44 (0) 20 7692 8790

Read more:
Bioelectric Medicine Market Projected to Witness Vigorous Expansion by 2017-2027 - Dagoretti News

Read the Rest...

The Hill’s Morning Report – Nearing witness vote, GOP rushes to acquit Trump | TheHill – The Hill

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on The Hill’s Morning Report – Nearing witness vote, GOP rushes to acquit Trump | TheHill – The Hill

Welcome to The Hills Morning Report. Happy Thursday! Our newsletter gets you up to speed on the most important developments in politics and policy, plus trends to watch. Alexis Simendinger and Al Weaver are the daily co-creators, so find us @asimendinger and @alweaver22 on Twitter and recommend the Morning Report to your friends. CLICK HERE to subscribe!

By the time nearly ten hours of questions from senators had paused for the night during President TrumpDonald John TrumpDemocrats outraged over White House lawyer's claim that some foreign involvement in elections is acceptable Senators take reins of impeachment trial in marathon question session White House announces task force to monitor coronavirus MOREs impeachment trial on Wednesday, the notion of acquittal on Friday with no witnesses had gained altitude in the Senate.

The trials format calls for another day of questions. Senators from both parties, taking their cues from their colleagues queries late Wednesday, said the prospect of 51 votes to call witnesses and prolong the trial appeared to have dimmed. To seek new evidence would require at least four Republicans to join every Democrat in the Senate in support of a motion to begin debate on the issue later this week.

Jay SekulowJay Alan SekulowGOP predicts Roberts won't cast tie-breaking vote on witnesses Live coverage: Senators query impeachment managers, Trump defense Trump lashes out at Bolton over 'nasty' and 'untrue' book MORE, the presidents personal attorney, said that if witnesses are called, We would be here for a very, very long time. And thats not good for the United States.

Thats a view shared by Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellDemocratic senator to force vote requiring Roberts to weigh in on witnesses Evangelical pastor: Jesus would have 'beat the crap' out of John Bolton Bolton's lawyer disputes NSC assessment that manuscript contains classified information MORE (R-Ky.), who believes calling witnesses would create a slippery slope for Trump, the Republican Party and for GOP senators, like himself, who will face the voters in November.

The Hill: On fascinating display on Wednesday: A struggle for influence between McConnell and Sen. Mitt RomneyWillard (Mitt) Mitt RomneySenators take reins of impeachment trial in marathon question session Overnight Defense: Bolton, GOP senators see close ties challenged | Republicans fume over Dem maneuver on Iran bills |Trump criticizes Democrats over war powers vote GOP predicts Roberts won't cast tie-breaking vote on witnesses MORE (R-Utah).

The Hill: Marathon question session put key senators in the spotlight.

Trump is all but assured of acquittal on allegations brought by House Democrats that he abused his presidential authority by soliciting help from Ukraine to try to dig up dirt on a presidential rival, then tried to stonewall Congress to cover it up. Senators from both parties do not dispute that two-thirds of the upper chamber will not vote to remove Trump from office on the basis of the arguments presented by the House prosecutors.

Motions that may be introduced on Friday to debate trial witnesses are expected to fall short of the support needed to try to depose former national security adviser John BoltonJohn BoltonSenators take reins of impeachment trial in marathon question session Democratic senator to force vote requiring Roberts to weigh in on witnesses Overnight Defense: Bolton, GOP senators see close ties challenged | Republicans fume over Dem maneuver on Iran bills |Trump criticizes Democrats over war powers vote MORE or any other top Trump aide. Democrats want to fortify accusations of a quid pro quo, or what the House impeachment managers argue was the presidents corrupt scheme to enlist the help of a foreign government to improve his chances of reelection.

The Wall Street Journal: Democrats say they are stunned by a Trump lawyers stance on campaign help from a foreign government.

Retired Harvard University professor and legal scholar Alan DershowitzAlan Morton DershowitzBolton, GOP senators see their close ties challenged Dershowitz: If President does something to win election, it's OK unless it's illegal Live coverage: Senators query impeachment managers, Trump defense MORE, a member of Trumps defense team, told senators on Wednesday that anything any president does to mix policy decisions with personal political considerations is in the public interest and cannot be impeachable.

The Hill: Some GOP senators are Bolton admirers. Theyre in a tough spot.

As Chief Justice John Roberts fielded queries submitted in writing, Sen. Ted CruzRafael (Ted) Edward CruzTed Cruz clarifies after Lev Parnas's lawyer calls senator's tweet 'fake news' John Roberts blocks Rand Paul's question on whistleblower Dershowitz: If President does something to win election, it's OK unless it's illegal MORE (R-Texas) asked if it mattered if there was a quid pro quo. No, responded Dershowitz, who maintained that presidents and politicians see the public good as an offshoot of their reelection. Thats why its so dangerous to try to psychoanalyze a president, he said (The Associated Press). The House impeachment managers, led by Intelligence Committee Chairman Adam SchiffAdam Bennett SchiffSenators take reins of impeachment trial in marathon question session How low will the president go? Live coverage: Senators query impeachment managers, Trump defense MORE (D-Calif.), dismissed Dershowitzs expansive interpretation of presidential self-interest.

Senate Republicans said they are confident Roberts will not cast a tie-breaking vote to decide whether to allow additional testimony from witnesses. According to The Hills Jordain Carney, GOP senators believe such a move would go against how Roberts views his role in the trial: As ceremonial arbitrator, unlikely to insert himself in a political brawl of this magnitude.

I certainly think its a very fraught topic, said Sen. Josh HawleyJoshua (Josh) David HawleyJohn Roberts blocks Rand Paul's question on whistleblower Democratic senator to force vote requiring Roberts to weigh in on witnesses GOP predicts Roberts won't cast tie-breaking vote on witnesses MORE (R-Mo.), noting that he had not talked to Roberts about the prospect. I would guess that he would not break a tie.

Senate Rules Committee Chairman Roy BluntRoy Dean BluntOvernight Defense: Bolton, GOP senators see close ties challenged | Republicans fume over Dem maneuver on Iran bills |Trump criticizes Democrats over war powers vote GOP predicts Roberts won't cast tie-breaking vote on witnesses Bolton, GOP senators see their close ties challenged MORE (R-Mo.) added that a 50-50 vote would mean the drive to call witnesses failed.

The New York Times: From defense teams broad version of Trumps public interest to Democrats warnings of a toothless future Senate, 6 takeaways from Wednesdays trial questions.

The Hill: Bolton lawyer disputes National Security Council assessment that classified secrets are included in his clients pending manuscript and must be deleted before publication.

NBC News: White House objects to publication of Boltons book, demands classified information be deleted first.

The Associated Press: Impeachment trial became more pointed with senators detailed back-and-forth questions, which continue today.

The Hill: Dem senator to force vote requiring Roberts to weigh in on witnesses.

LEADING THE DAY

CAMPAIGNS & POLITICS: He might not be competing in the first four contests of the Democratic primary, but former New York City Mayor Michael BloombergMichael Rubens BloombergWarren gets endorsements from 45 Michigan officeholders, activists Poll: Most Democratic voters say billionaires are out of touch with average American The Hill's 12:30 Report: Impeachment trial moves to senators' questions MORE is grabbing the attention of former Vice President Joe BidenJoe BidenSenators take reins of impeachment trial in marathon question session Sanders campaign says it raised more than .3 million in one day after negative ad Warren's dog campaigns in Iowa while senator sits in impeachment trial MOREs campaign.

As Jonathan Easley and Amie Parnes report, allies of the former vice president are growing anxious about Bloombergs presence in the race and potential effect on Super Tuesday, when 13 states (plus American Samoa) will hold their contests. Specifically, they argue the former mayor could siphon off support from Biden pave the way for Sen. Bernie SandersBernie SandersSanders campaign says it raised more than .3 million in one day after negative ad Warren's dog campaigns in Iowa while senator sits in impeachment trial Weld bets on New Hampshire to fuel long shot bid against Trump MORE (I-Vt.) to nab the Democratic nomination.

Even if Biden successfully beats back challenges from centrists such as former South Bend, Ind., Mayor Pete ButtigiegPeter (Pete) Paul ButtigiegSanders campaign says it raised more than .3 million in one day after negative ad Warren's dog campaigns in Iowa while senator sits in impeachment trial Overnight Health Care Presented by Philip Morris International Dems warn Trump against Medicaid block grants | Sanders under pressure on how to pay for 'Medicare for All' | China to allow in US health officials to study coronavirus MORE and Sen. Amy KlobucharAmy Jean KlobucharWarren's dog campaigns in Iowa while senator sits in impeachment trial Minneapolis NAACP, Black Lives Matter call on Klobuchar to suspend campaign Live coverage: Senators query impeachment managers, Trump defense MORE (D-Minn.) in early-voting states, headlined by Iowa and New Hampshire, hell have Bloomberg waiting for him on March 3, when nearly 40 percent of convention delegates are up for grabs.

There is a lot of overlap between the supporters of the two septuagenarian candidates as they both have deep ties to the Democratic establishment and long relationships with some of the partys premier donors.

The issue potentially facing the two mirrors the one faced by Republicans who opposed Trump in the 2016 GOP primary, where they were unable to settle on one alternative candidate or strategy and Trump rolled without issue toward the nomination.

The Washington Post: Biden, Sanders allies have spoken to Andrew YangAndrew YangComedian Dave Chappelle will campaign with Yang in South Carolina Yang says it 'wouldn't be surprising' if many of his supporters back Sanders in Iowa Gabbard says she's received no reason from CNN for lack of invitation to town halls MOREs campaign about caucus night cooperation.

The Associated Press: Biden under pressure to prove he can thwart new GOP attacks.

While Biden worries about the looming threat from Bloomberg, the danger is more immediate for Sen. Elizabeth WarrenElizabeth Ann WarrenSanders campaign says it raised more than .3 million in one day after negative ad Warren's dog campaigns in Iowa while senator sits in impeachment trial Weld bets on New Hampshire to fuel long shot bid against Trump MORE (D-Mass.). She has seen her support levels fall in recent weeks, putting her in fourth place in both Iowa and New Hampshire according to the latest RealClearPolitics polling average.

Her current standing is in stark contrast to only three months ago when she was riding high and could credibly claim the mantle as the front-runner for the Democratic nod.

In his latest memo, Niall Stanage examines Warrens bid and what she needs to do in the coming weeks to survive the early states and eventually land her back into position to contend for the nomination.

The New York Times: Elizabeth Warrens Iowa pivot: from her plans to her plan to win.

The Hill: Poll: Biden leads in Iowa, with Sanders in close second.

Jonathan Allen: Rival campaigns say Trump Ukraine hits are a warning to Biden.

The Hill: Minneapolis NAACP, Black Lives Matter call on Klobuchar to suspend campaign.

IN FOCUS/SHARP TAKES

WHITE HOUSE & ADMINISTRATION: The Trump administration on Wednesday evacuated about 200 U.S. personnel and citizens to California from China as the death toll from the coronavirus rose to 170 and the transmission rate continued to surge in a nation of 1.3 billion people.

The White House announced a domestic task force to monitor the situation with Health and Human Services Secretary Alex Azar in the lead (The Hill).

The health commission for Hubei Province said today that the virus is spreading by 1,000 confirmed cases per day (The Washington Post), pushing the total number of people sickened by the virus closer to 8,000. Patients are being treated in at least 16 countries (Reuters).

The World Health Organization will convene an emergency meeting today in Geneva to discuss whether the microscopic organism now poses a public health emergency because of its rapid spread.

In the last few days the progress of the virus, especially in some countries, especially human-to-human transmission, worries us, WHO Director-General Tedros Adhanom Ghebreyesus told a news conference on Wednesday, naming Germany, Vietnam and Japan. Although the numbers outside China are still relatively small, they hold the potential for a much larger outbreak.

Five cases have been diagnosed in the United States in patients who traveled to the epicenter of the outbreak in China. HHS is not handling the virus as a public health emergency domestically, but medical experts are concerned about the human-to-human transmission rate seen in China, according to an article in the New England Journal of Medicine (The Associated Press).

As countries assess their preparedness for any epidemic or potential pandemic, officials with Americas public health infrastructure in states and localities say their budgets are stretched thin (The Hill). Trump has been criticized by Democrats for eliminating a senior director position for global health security and biothreats at the National Security Council during his presidency and for repeatedly proposing budget cuts to the Centers for Disease Control and Prevention and the National Institutes for Health (The Associated Press).

The Washington Post has mapped the ongoing spread of the coronavirus in China and around the globe HERE.

> Trade: Trump, with fanfare and an assembled audience on the South Lawn on Wednesday, officially signed the replacement for the North American Free Trade Agreement known as the U.S.-Mexico-Canada Agreement (The Hill).

The president praised the bipartisan ratification of the revised hemispheric pact, but limited his public accolades to Republican senators (Democrats werent invited), joking that in the midst of an impeachment trial, Maybe Im just being nice because I want their vote. I dont want to leave anyone out.

The New York Times: Whats in the USMCA trade pact signed by the president?

Read more from the original source:
The Hill's Morning Report - Nearing witness vote, GOP rushes to acquit Trump | TheHill - The Hill

Read the Rest...

Homoeopathy for coronavirus: Is AYUSH commitment to alt meds healthy or promoting quackery? – ThePrint

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Homoeopathy for coronavirus: Is AYUSH commitment to alt meds healthy or promoting quackery? – ThePrint

Text Size:A- A+

AYUSH ministry issued a health advisory Wednesday for the prevention of coronavirus infections through homoeopathy and Ayurveda. It included recommendations such as taking 500 mg of samshamani vati twice a day and putting two drops of sesame oil in each nostril every morning. India is now among the countries which are at high risk from virus outbreak.

ThePrint asks: Homoeopathy for coronavirus: Is AYUSH commitment to alt meds healthy or promoting quackery?

Keshav DesirajuFormer health secretary

When it comes to a public health crisis, there is no time to waste. I believe the coronavirus is a matter of great concern, considering the Director General of WHO recently called on Chinese President Xi Jinping.

On AYUSHs latest advisory on coronavirus, I will say that homoeopathy practitioners are free to work and prescribe medicines within their framework. AYUSH training institutions, whether its those in Uttar Pradesh that specialise in Ayurveda and Unani or those in Tamil Nadu that specialise in Siddha, are meant to develop a workforce that operates strictly within their authorisation. Also, patients coming to AYUSH practitioners should specifically seek AYUSH remedies. Homoeopathy should not be treated as an alternative to western medicine as outlined in the Medical Council Act, 1956. Also, its a bit early to say that the AYUSH advisory is the Narendra Modi governments only response.

I believe we should not wait to see how the coronavirus epidemic snowballs. Im sure the Directorate General of Health Services under the Ministry of Health has sounded all the alarm bells and is committed to evacuating Indians from China and putting in place a system for their entry in India.

Sumaiya ShaikhNeuroscientist, author and Editor, AltNews

Homoeopathy is the least scientific among various forms of alternative therapies. It has no evidence of treating major disorders, including the latest threat of coronavirus infections. Reviews of research conducted by homoeopaths have revealed data manipulations, overstretching of results, and statistical frauds to conclude their efficacy. The research has not only been found to be of sub-quality and inconsistent with the mechanisms of evidence-based drug research, but also difficult to replicate in large-scale studies.

Evidence-based medicine takes years, if not decades, to develop. Alternative treatments for newly found diseases emerge with claims of treating them within days or weeks, the microscopic structure of the virus was not found until 1931.

Homoeopathy research remains a waste of tax-payers money and should not be a part of public healthcare. Its drug packaging in the market should include appropriate labelling of any evidence (rather a lack of) reported in its research studies.

Moreover, government platforms suggesting the use of homoeopathy during a deadly pandemic is nothing short of irresponsible. While governments in the West are excluding homoeopathy from public health, India has been consistently adding value to it and other alternative drugs that have little scientific evidence to support their claims.

Piyush I. JoshiSecretary General, Homoeopathic Medical Association of India

Homoeopathy is not quackery and has had a long tradition of preventive support for all types of infections. It even played a significant role in the 1980 influenza epidemic.

The exact clinical picture of coronavirus is missing as of now, which means comprehensive examinations and studies of its severity are of extreme necessity. However, this is a job for clinical laboratories that risk a patients life for the sake of research. The world has pumped in a lot of time and money into studying patients with diseases like AIDS and yet they remain incurable.

Homoeopathy serves not just as a preventive measure, but as a simultaneous process of studying a patients symptoms and treating them effectively. It focuses on symptoms that function as reflections of the internal disease. So, it is not premature to apply homoeopathy to patients infected by coronavirus, even though it is a new and relatively unknown virus. Homoeopathy is scientific.

Homoeopathy takes a holistic approach to study a patients experience with the disease and observations noted by relatives. It also derives common bases between patients and considers the chronology of symptoms. Only then a remedy is put forth. AYUSHs advisory on preventing coronavirus may appear generic, but they are the fundamentals of hygiene and maintaining an immune system that can fight such dangerous diseases.

RV AsokanSecretary General, Indian Medical Association

AYUSH is promoting quackery in its latest advisory on preventing coronavirus. While I do believe that Ayurveda and other forms of naturopathy are an integral part of the history of medicine, modern medicine is more transparent and understands its limitations. We remain responsible for what we say and advise.

Any preventive scientific method has to follow certain basic standards. A simple vaccine, for example, must undergo a double-blind test in order to reproduce results in an unbiased manner. Homoeopathy does not follow standard protocols and most of its methods are based on surmises.

Medicine and its different systems have evolved over centuries. Advances in modern medicine are transparent and in public domain. The same cannot be said about others. They need to evaluate their advances from ancient concepts. If a medical discipline lacks basic pharmacopoeia and is not transparent about the possible side effects of a particular drug, then it is not scientific.

I think the reason India has the worlds largest administrative framework for homoeopathy is that we as a nation need to work on our scientific temperament.

Also read:Economist, Soros: Has Hindu nationalism increased global criticism of India or bad economy?

By Pia Krishnankutty, journalist with ThePrint

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Link:
Homoeopathy for coronavirus: Is AYUSH commitment to alt meds healthy or promoting quackery? - ThePrint

Read the Rest...

Stephen Moore: Low interest rates are the economy’s unsung hero – Oklahoman.com

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Stephen Moore: Low interest rates are the economy’s unsung hero – Oklahoman.com

Third, low interest rates reduce the cost of borrowing costs for businesses and allow small firms that might not have access to equity markets to expand investment through loans. By the way, real (inflation-adjusted) interest rates rise when there is a higher demand for credit, which happened in the 1980s even as nominal rates plummeted.

The biggest winner of all from low rates is, of course, Uncle Sam. Every 1-percentage-point reduction in interest rates reduces federal borrowing costs by at least $1 trillion over a decade. A sudden spike in rates by, say, 200 basis points, which would still be below the historical average in the post-World War II era, means $2 trillion to $3 trillion of higher interest expenditures on top of $20 trillion of publicly traded debt.

A final point: I keep hearing senior citizens and financial advisers complain that low interest rates hurt retirees on fixed incomes. That's nonsense. Seniors tend to hold more stocks than young people, so the surge in stock values has disproportionately benefited older people in the United States. Seniors who complain about today's low returns on bonds should be taking a look at how their stock portfolios are performing. In just three years under Trump, index funds have seen better than a 50% return. Some $60 trillion of wealth is held by seniors today and will soon be passed on to the younger generations thanks to this 40-year surge in the stock market.

In the 1970s, seniors living on fixed incomes were supposed victims of high inflation and interest rates because it cost them more to buy food, medicine and energy. Higher interest rates would correspond with a higher cost of living, so seniors should be careful of what they wish for.

So should Trump. His administration is benefiting mightily from low rates and tame inflation to which his supply-side policies, including tax cuts, have contributed. But negative rates would mean falling prices, and the last time that happened, the nation found itself heading into the Great Depression.

Stephen Moore is a senior fellow at the Heritage Foundation and an economic consultant with FreedomWorks.

CREATORS.COM

(Story continued below...)

Excerpt from:
Stephen Moore: Low interest rates are the economy's unsung hero - Oklahoman.com

Read the Rest...

Virus in China affects Canada’s track and field team, other sports – Medicine Hat News

§ January 30th, 2020 § Filed under Nano Medicine Comments Off on Virus in China affects Canada’s track and field team, other sports – Medicine Hat News

By Lori Ewing, The Canadian Press on January 29, 2020.

Six months before the 2020 Tokyo Olympics, the spread of a new virus in China has thrown a wrench into competitive plans for Canadian track and field athletes.

Amid growing concern about the new coronavirus that had killed 132 people as of Wednesday, the indoor world athletics championships March 13-15 in Nanjing, China have been postponed by a year. The championships are one of several international sports and Olympic qualifying tournaments that have been either postponed, cancelled or moved elsewhere.

Simon Nathan, Athletics Canadas high performance director, said Canada expected to field a team of about 20 in Nanjing, including decathlete Pierce LePage, pole vaulters Alysha Newman and Shawn Barber, thrower Brittany Crew, high jumper Mike Mason and middle-distance runners Gabriela DeBues-Stafford and Melissa Bishop, and a womens 4400 relay team.

Nathan said athletes most affected, however, would be those on the bubble for Olympic qualifying. While athletes can qualify by achieving a time or height or distance, the remaining spots in events will be filled through a complicated world ranking points system.

And there were huge bonus points for the world indoor championships, Nathan said. And so people will miss out on the opportunity.

The governing body of athletics said the indoor worlds will now be held in March 2021 instead of March 13-15 this year.

With the Olympics opening in late July, Nathan said Canadas track and field athletes would plan to peak in both March and then at the Olympics. He said advisers, including the teams head coach Glenroy Gilbert, would meet individually with the athletes who had planned to compete in Nanjing, which is 530 kilometres from Wuhan, where the virus emerged.

If they need to refocus or redo that, well try and find different competitions for each of them, but theyll likely be spread out rather than in one place, which is what would have happened at the world indoors, he said.

The international ski federation cancelled the first World Cup races scheduled for the mountain venue where the sport will be held during the 2022 Beijing Olympics.

In alpine skiing, a mens downhill had been scheduled for Feb. 15 in Yanqing to start a two-race weekend.

Due to the outbreak and continuing spread of the Novel Coronavirus, FIS, the Chinese Ski Association and its Yanqing Local Organizing Committee, have jointly decided to cancel, FIS said in a statement.

The ski federation said it would advise later if the downhill and super-G races will be rescheduled.

That followed a decision by the international field hockey federation to postpone Pro League games in China. Qualifying tournaments for the Tokyo Olympics in soccer, basketball and boxing scheduled for next month have been moved outside of the country.

The biggest upcoming event in China is the Formula One race in Shanghai on April 19, which draws large crowds both for the race and for practice and qualifying.

Olympic qualifying events have been affected in recent days. Womens soccer and womens basketball games were moved to Australia and Serbia. The soccer games had already previously moved from Wuhan, at the centre of the outbreak, to Nanjing. Boxing tournaments for the Asia and Oceania regions will be held in Jordan in March.

Tokyo Governor Yuriko Koike acknowledged her concern about the virus when speaking Wednesday to the heads of 62 municipalities.

With only 177 days to go and our preparations accelerating, we must firmly tackle the new coronavirus to contain it, or we are going to regret it, Koike said. I will do the utmost to contain this new problem as we co-operate closely with all of you.

Tokyo Olympic organizers put out a generic statement on Wednesday and offered no details.

Countermeasures against infectious diseases constitute an important part of our plans to host a safe and secure games, the statement said, adding they would carefully monitor any incidence of infectious diseases and we will review any countermeasures that may be necessary with all relevant organizations.

More than 130 deaths in China have been recorded because of the disease, including the first in Beijing. On Wednesday, the number of total cases jumped to 5,974.

Cases have been reported in Japan, South Korea, Thailand, Vietnam, the United States, Australia, Canada and Germany.

The coronavirus family includes the common cold but also more severe illnesses. It causes cold- and flu-like symptoms, and in more severe cases, shortness of breath and pneumonia. The virus is thought to have spread to people from wild animals sold at a market in Wuhan, a city of 11 million people which is now in lockdown.

Future sports events in China also include a World Cup soccer qualifying game on March 26 against Maldives, and the China Open golf tournament, part of the European Tour, on April 23-26 in Shenzhen.

Also Wednesday, Danish soccer club Aalborg said it had decided not to play a friendly against Chinese team Wuhan Zall in Spain.

We are aware that the risk of infection may be microscopic, and little is still known about the virus, but in consultation with the (club), management, staff and the health sector, we have agreed not to expose anyone, Aalborg managing director Thomas Baelum said.

With files from The Associated Press.

You must be logged in to post a comment.

Link:
Virus in China affects Canada's track and field team, other sports - Medicine Hat News

Read the Rest...

Cape Breton University researchers hope to help water woes – TheChronicleHerald.ca

§ January 29th, 2020 § Filed under Nano Medicine Comments Off on Cape Breton University researchers hope to help water woes – TheChronicleHerald.ca

SYDNEY, N.S.

Work taking place at Cape Breton University could help small communities both locally and globally deal with water contamination issues.

Shine (Xu) Zhang is a CBU chemistry professor and holds the Tier II Canada Research Chair in healthy environments and communities and the industrial research chair in applied nanotechnology. He is working on a project that involves electrochemical water treatment which he believes can offer a green, efficient and cost-effective alternative.

Water pollution, water contamination is a global concern but its also a local problem for Cape Breton and Nova Scotia, Zhang said.

He said he wanted to take on water contamination as a research topic because it is such a big issue.

CBU is a local university, but CBU really wants to contribute to the community, Zhang said. The environment is a big issue. Water contamination is also a global issue, therefore, research here, if we do a good job, can not only help local communities but also help people far away from here.

We want to apply what we learn to solve some real-world problems.

His research program aims at exploiting nanotechnology and nanomaterials for environmental and health applications with a focus on water treatment, cancer diagnostics and treatment with precision nanomedicine. Zhang has published 65 journal articles.

He describes the technology hes developed as being relatively simple, with an electrode acting like a filter. One electrode removed organic material while another electrode removed heavy metals.

Water comes through the filter, dirty water becomes clean, Zhang said.

The technology, I feel is useful because, from a research standpoint, energy consumption is very low, so essentially its quite cost-effective. That is compatible, for example, with solar panel, those kinds of various sustainable power source. It can be a very automatic system, so you dont need a lot of manpower to run it.

A request for proposals for a market research consultant issued by CBU recently closed and Zhangs team is currently reviewing the proposals received. It asked for proposals to outline how the consultant would go about understanding and marketing the technology, from lab to market through the successful negotiation of a licence.

Zhang said they are now evaluating the best way to commercialize the technology.

Were looking for different industry partners so that we can do further development of specific products or applications for this to meet different needs, he said. For example, we work with environmental remediation companies, we work with landfill leachate, we work on pharmaceutical wastewater. We want to find industry partners to work on further development.

Its hoped the consultant that they hire will assist in finding those partners. A prototype has been developed.

The ideal starting industry level would be 3,000 litres a day, were about halfway there already, were at about 1,500 litres a day," said Andrew Carrier, who works closely with Zhang.

Carrier noted the technology also works in flows, so you dont need a large quantity of contaminated water to make use of it, and it doesnt take up much physical space. They want the technology to be accessible to as many people who can make use of it as possible, he added.

Its easy to put into a remote location without having to invest much capital, Carrier said.

Zhang noted the technology also doesnt generate any sort of secondary waste as a result of its water treatment.

Zhangs work has been supported by the Atlantic Canada Opportunities Agency, Innovacorp, Springboard Innovation Mobilization program, Nova Scotia Lands as well as CBU.

RELATED:

View original post here:
Cape Breton University researchers hope to help water woes - TheChronicleHerald.ca

Read the Rest...

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603 | Small Molecules | News Channels -…

§ January 29th, 2020 § Filed under Nano Medicine Comments Off on Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603 | Small Molecules | News Channels -…

DetailsCategory: Small MoleculesPublished on Tuesday, 28 January 2020 18:38Hits: 233

MACCLESFIELD, UK I January 28, 2020 I Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis.

The IND is a crucial milestone in the continued development of BB2603, a nanoformulated, topical form of terbinafine for the treatment of onychomycosis (fungal toenail). With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.

The primary outcome of this study is to look at the efficacy BB2603 in onychomycosis, with a secondary dose finding outcome also being investigated.

John Ridden, CEO said: Having received clearance from the FDA we are looking forward to the opportunity to work with over 20 international sites on the Phase IIb trial of BB2603 with the first patient expected to be recruited in March 2020.This is a key milestone in our path to commercialisation of our nanotechnology product portfolio.

With BB2603, Blueberry Therapeutics aim to maintain the efficacy of the oral gold standard treatment, but at a lower dose. Delivering the active pharmaceutical ingredient using nanotechnology ensures it penetrates across the nail plate and reaches the target site of action in a controlled manner, meaning lower doses can be used and systemic side effects are minimised.

About Blueberry Therapeutics Limited

Blueberry Therapeutics Ltd., incorporated in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections. The company is using its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.

Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market. For more information, please visit http://www.blueberrytherapeutics.com

SOURCE: Blueberry Therapeutics

Read more:
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603 | Small Molecules | News Channels -...

Read the Rest...

How IoMT Comes to the Rescue of Patients and Clinicians Facing… – Medical Tech Outlook

§ January 29th, 2020 § Filed under Nano Medicine Comments Off on How IoMT Comes to the Rescue of Patients and Clinicians Facing… – Medical Tech Outlook

With the barriers to access hearth services are increasing exponentially, the number of patients and clinicians adopting connected medical devices is also growing.

FREMONT, CA:This eras interconnected devices are being designed to enhance proficiencies, reduce the care expenses, and drive better outcomes in healthcare. With the improvement in computing power and wireless capabilities, enterprises are leveraging the potential of the Internet of Medical Things (IoMT) technologies.

IoMT possesses the ability to allocate, analyze, and transmit health data, thus improving healthcare delivery. These applications play a significant role in the lives of patients and clinicians as these apps help in tracking and preventing chronic diseases.

IoMTs potential in healthcare

IoMTs capabilities include fewer errors, accurate diagnosis, and lower costs of care. By pairing it with smartphone applications, the technology enables patients to send their health data to their doctors for better surveillance of their diseases as well as tracking and preventing chronic illnesses.

For example, the Fitbit smartwatch helps in evaluating the patients with ischemic heart disease more accurately by recording their heart rate and accelerometer data at the same time. These kinds of technologies not only enhance the patient experience by eradicating the requirement for in-person medical visits but also help in reducing healthcare expenses.

IoMT also contributes to drug management by introducing smart pills that contain microscopic sensors, which on swallowing, transmit data to connected devices.

Some digital medicine companies like Proteus Discover emphasize the capabilities of their smart pills on measuring medication treatment effectiveness for enhancing clinical outcomes. Other companies are utilizing the pills for monitoring the internal health of the patients, which wirelessly transmit data like measurements of core temperature that are vital in life and death scenarios.

IoMT is growing

According to the report of AllTheResearch, the smart wearable device segment of IoMT, which includes smartwatches and sensor-laden smart shirts as well, has secured their most significant share of the global market in 2019, at roughly 27 percent.

This specific domain of IoMT is positioned for even additional growth as AI is incorporated into the connected devices and is capable of real-time analysis and remote measurement of patient data.

The expansion of the IoMT ecosystem is also providing opportunities to other technologies to flourish like kiosks that can provide connectivity to care providers. These kiosks help clinicians in monitoring and treating patients remotely, which is a critical need for patients in rural communities who struggle to recruit and retail, medical specialists.

The evolution of the IoMT ecosystem will continue to become increasingly impactful no matter where the patient is and what the condition is. The patients and clinicians in remote areas will benefit significantly as they will have better access to care through connected medical devices.

More:
How IoMT Comes to the Rescue of Patients and Clinicians Facing... - Medical Tech Outlook

Read the Rest...

Mans headache turns out to be a tapeworm that burrowed in his brain a decade earlier – The Sun

§ January 29th, 2020 § Filed under Nano Medicine Comments Off on Mans headache turns out to be a tapeworm that burrowed in his brain a decade earlier – The Sun

A MAN was left horrified after doctors discovered a 4cm tapeworm had been burrowed in his brain for over a decade.

The unnamed patient, from Austin, Texas, believes he developed the parasitic infection as a result of eating under-cooked pork while he was in Mexico.

4

Known only by the name Gerardo, the man claimed he first suspected something was wrong when he began experiencing extreme headaches.

And he told CBS 21 that sometimes they became so sever they'd make him nauseous.

He said: "It's very intense, very strong...it made me sweat too, sweat from the pain, pain in the head and then I would vomit from the pain."

However, things took a turn for the worst last year when Gerardo passed out on the field during a football match.

4

He decided to get himself checked out and it was then that Dr Jordan Amadio, a neurosurgeon at Dell Seton Medical Center, made a shocking discovery.

A brain scan revealed a mass sitting near Gerardo's brain stem and it appeared to be about 4cm long.

Medics decided to carry out further tests, which ruled out a tumour.

Doctors soon realised it was a "pretty big" tapeworm, which could have killed Gerardo if it had gone undetected much longer, claimed Dr Amadio.

4

Gerardo had urgent surgery to remove the tapeworm and he is now expected to make a full recovery.

Doctors have revealed that Gerardo had a type of infection called neurocysticercosis, which is the result of accidental ingestion of eggs of a tapeworm called Taenia solium.

Taenia Solium often infects pigs, laying larvae in them.

If pork isn't properly cooked, humans can end up eating these larvae, which hatch in the intestines.

If people don't pass the worms, their life cycle will continue, Taenia Solium will lay its eggs in the person's body.

4

These larvae develop in sacs or cysts, that can travel around the body, in rare cases, reaching the brain as Gerardo's did.

His surgeon is now warning people that this infection can easily go "undetected" and has urged medical professionals to be "more aware" of it.

Dr Amadio said: "This can go undetected for years, so you can eat by accident a microscopic egg from the tapeworm larva and not know it for years.

"They can grow inside the body without causing symptoms until they get big enough."

He added: "There's something, I think definitely for every medical professional to be aware of.

Tapeworms: the facts and figures

wing & a slayer How bats are our worst enemy behind deaths of millions by horrific diseases

FATAL ERRORS Nurse died of cervical cancer after being told six times she didnt have it

NEW WAVE Fears over rise in coronavirus cases in patients who've NEVER been to China

ON EDGE NHS staff prepare for 'infectious' bodies as coronavirus 'will hit Britain in days'

KILLER CRISIS Coronavirus will last MONTHS & vaccine trials weeks away as deaths hit 132

SCREEN TOTS Kids who are glued to a screen at three-years-old 'are couch potatoes by five'

ENERGY WATCH Energy drinks 'increase risk of heart problems, seizures and death'

HIGH ALERT Fears 'many more' Brits infected by coronavirus as 9 patients are tested in UK

MUM'S INSTINCT Mum branded 'dramatic' by medics she begged not to discharge baby who died

"It is not commonly seen and can actually masquerade as different things."

Tapeworm infections are rare in the UK, but are fairly common in other parts of the world.

Tapeworms can grow up to 55ft long and can survive in the intestine as long as 25 years.

Read more:
Mans headache turns out to be a tapeworm that burrowed in his brain a decade earlier - The Sun

Read the Rest...

« Older Entries Newer Entries »



Page 30«..1020..29303132..4050..»